USADA announced today that Pamela Spuehler of Chula Vista, CA, an athlete in the sport of field hockey, has tested positive for a prohibited substance and accepted a suspension for her doping offense.
Spuehler, 25, tested positive for Canrenone, a diuretic, as the result of an out-of-competition sample collected on September 14, 2011. Diuretics are prohibited under the USADA Protocol for Olympic and Paralympic Movement Testing and the International Hockey Federation (FIH) anti-doping rules, both of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.
Spuehler accepted a two-month period of ineligibility, which began on September 28, 2011, the day USADA received notice of the adverse finding, and will end on November 30, 2011. As a result of the sanction, Spuehler is also disqualified from all results obtained on or subsequent to September 14, 2011, the day her urine sample was collected, including forfeiture of any medals, points and prizes.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
For more information or media inquiries, click here.